KOPRANNSEKopran Limited· PharmaceuticalsLowNeutral
Announced Mon, 18 May · 19:50 IST

Kopran Limited has informed the Exchange regarding Appointment of as Non- Executive Independent Director in its Subsidiary company w.e.f. May 18, 2026.

Management Changes View source PDF

KOPRAN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+2.4%1-day move
₹164.00
prior close
₹165.75
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.4+0.3+1.1+1.0+2.4+1.4+0.0+15.2+17.8+25.3+10.7+18.3+23.8
Up moveDown movePending
AI summary

Kopran Limited's subsidiary, Kopran Research Laboratories Limited (KRLL), has appointed Mr. Chandresh Gandhi as Additional Director (Non-Executive, Independent Category) for a term of 5 years starting May 18, 2026. Mr. Gandhi is already an Independent Director on the parent company board. Additionally, KRLL will issue rights shares in the ratio of 1:12 (one share for every 12 held) at a face value of Rs 10 with a premium of Rs 90 per share, raising Rs 18.75 crore for working capital requirements.

Likely market impact

This appointment brings experienced financial and audit expertise to the subsidiary's board. The rights issue will strengthen the subsidiary's balance sheet and support its working capital needs, which could benefit Kopran Limited's consolidated financials.